ReviewmBio2023
Defining the Benefits of Antibiotic Resistance in Commensals and the Scope for Resistance Optimization.
Review in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Dietary and nutritional strategies for reducing disease risk associated with antibiotic-induced dysbiosis.Gut microbes · 2026Review
- Quantifying antibiotic susceptibility and inoculum effects using transient dynamics of Pseudomonas aeruginosa.PLoS computational biology · 2026Article
- Modelling the role of the microbiome in antimicrobial resistance across scales.Nature microbiology · 2026Review
- Assessing the Ecological Roles of Resistomes within Microbial Communities in Antibiotic-contaminated Ecosystems.Microbial ecology · 2026Review
- Containment of antimicrobial resistance for strengthening global public health security: Biorisk management perspectives.Biosafety and health · 2026Review
- A Review of Doxycycline Post-Exposure Prophylaxis and Its Implications for Antimicrobial Resistance and the Human Microbiome.Infectious diseases and therapy · 2026Review
- Microbial Primer: Challenges and opportunities in the treatment of chronic polymicrobial infections ‒ an eco-evolutionary perspective.Microbiology (Reading, England) · 2025Review
- Biocides as drivers of antibiotic resistance: A critical review of environmental implications and public health risks.Environmental science and ecotechnology · 2025Review
- Acquired Bacterial Resistance to Antibiotics and Resistance Genes: From Past to Future.Antibiotics (Basel, Switzerland) · 2025Review
- Clostridium scindens: history and current outlook for a keystone species in the mammalian gut involved in bile acid and steroid metabolism.FEMS microbiology reviews · 2025Review
- Article
- A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation.Signal transduction and targeted therapy · 2024Review
- Review
- Antimicrobial Resistance in Equines: A Growing Threat to Horse Health and Beyond-A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2024Review
- The impact of phage and phage resistance on microbial community dynamics.PLoS biology · 2024Article
- Commensal antimicrobial resistance mediates microbiome resilience to antibiotic disruption.Science translational medicine · 2024Article
- Antibiotic resistance in bacterial communities.Current opinion in microbiology · 2023Review
- Gut microbiota interspecies interactions shape the response of Clostridioides difficile to clinically relevant antibiotics.PLoS biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Antibiotic resistance is a major medical and public health challenge, characterized by global increases in the prevalence of resistant strains. The conventional view is that all antibiotic resistance is problematic, even when not in pathogens. Resistance in commensal bacteria poses risks, as resistant organisms can provide a reservoir of resistance genes that can be horizontally transferred to pathogens or may themselves cause opportunistic infections in the future. While these risks are real, we propose that commensal resistance can also generate benefits during antibiotic treatment of human infection, by promoting continued ecological suppression of pathogens. To define and illustrate this alternative conceptual perspective, we use a two-species mathematical model to identify the necessary and sufficient ecological conditions for beneficial resistance. We show that the benefits are limited to species (or strain) interactions where commensals suppress pathogen growth and are maximized when commensals compete with, rather than prey on or otherwise exploit pathogens. By identifying benefits of commensal resistance, we propose that rather than strictly minimizing all resistance, resistance management may be better viewed as an optimization problem. We discuss implications in two applied contexts: bystander (nontarget) selection within commensal microbiomes and pathogen treatment given polymicrobial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.